DE60041548D1 - Substituierte pyridine und pyridazine mit angiogenesis hemmender wirkung - Google Patents

Substituierte pyridine und pyridazine mit angiogenesis hemmender wirkung

Info

Publication number
DE60041548D1
DE60041548D1 DE60041548T DE60041548T DE60041548D1 DE 60041548 D1 DE60041548 D1 DE 60041548D1 DE 60041548 T DE60041548 T DE 60041548T DE 60041548 T DE60041548 T DE 60041548T DE 60041548 D1 DE60041548 D1 DE 60041548D1
Authority
DE
Germany
Prior art keywords
hammender
pyridazine
angiogenesis
effect
substituted pyridines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60041548T
Other languages
German (de)
English (en)
Inventor
Jacques P Dumas
Teddy Kite Joe
Harold C Kluender
Wendy Lee
Dhanapalan Nagarathnam
Robert N Sibley
Ning Su
Stephen James Boyer
Julie A Dixon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Application granted granted Critical
Publication of DE60041548D1 publication Critical patent/DE60041548D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
DE60041548T 1999-09-28 2000-09-26 Substituierte pyridine und pyridazine mit angiogenesis hemmender wirkung Expired - Lifetime DE60041548D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40760099A 1999-09-28 1999-09-28
PCT/US2000/026500 WO2001023375A2 (en) 1999-09-28 2000-09-26 Substituted pyridines and pyridazines with angiogenesis inhibiting activity

Publications (1)

Publication Number Publication Date
DE60041548D1 true DE60041548D1 (de) 2009-03-26

Family

ID=23612752

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60041548T Expired - Lifetime DE60041548D1 (de) 1999-09-28 2000-09-26 Substituierte pyridine und pyridazine mit angiogenesis hemmender wirkung

Country Status (35)

Country Link
EP (1) EP1228063B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP4919567B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (3) KR100895571B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (3) CN100374435C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (3) AR025752A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE422494T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU782820B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG65860B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0014382B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2385817C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO5200835A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ304767B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE60041548D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DO (1) DOP2000000070A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EE (1) EE05258B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2320525T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GT (1) GT200000158A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20020308A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU230223B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (3) IL148880A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA25563A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA02003156A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (3) MY143377A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO20021520L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ518589A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PA (1) PA8503201A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20010607A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL205957B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (1) RS50369B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2260008C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK287417B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW593315B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA75053C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2001023375A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200202760B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1311500A2 (en) * 2000-08-09 2003-05-21 AstraZeneca AB Indole, azaindole and indazole derivatives having vegf inhibiting activity
CN101024627A (zh) 2000-10-20 2007-08-29 卫材R&D管理有限公司 含氮芳环衍生物
WO2003059354A2 (en) * 2001-12-21 2003-07-24 Bayer Pharmaceuticals Corporation Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
TWI299664B (en) 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds
CA2518530A1 (en) * 2003-03-11 2004-09-23 Novartis Ag Use of isoquinoline derivatives for treating cancer and map kinase related diseases
US20070082910A1 (en) * 2003-04-08 2007-04-12 Mitsubishi Pharma Corporation Specific nad(p)h oxidase inhibitor
EP1683785B1 (en) 2003-11-11 2013-10-16 Eisai R&D Management Co., Ltd. Urea derivative and process for producing the same
KR100553398B1 (ko) * 2004-03-12 2006-02-16 한미약품 주식회사 티에노[3,2-ｃ]피리딘 유도체의 제조 방법 및 이에사용되는 중간체
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
EP1797877A4 (en) 2004-09-13 2010-12-15 Eisai Co Ltd JOINT USE OF A SULFONAMIDE-BASED COMPOUND AND AN ANGIOGENESIS INHIBITOR
AU2005283422C1 (en) 2004-09-17 2017-02-02 Eisai R & D Management Co., Ltd. Medicinal composition
WO2007015578A1 (ja) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
JP2009533479A (ja) * 2006-04-15 2009-09-17 バイエル・ヘルスケア・アクチェンゲゼルシャフト 肺高血圧症処置用化合物
WO2007136103A1 (ja) 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. 甲状腺癌に対する抗腫瘍剤
JP5368096B2 (ja) 2006-08-28 2013-12-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌に対する抗腫瘍剤
EP2119707B1 (en) 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
AU2008325608B2 (en) 2007-11-09 2013-03-14 Eisai R & D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
CN101481380B (zh) 2008-01-08 2012-10-17 浙江医药股份有限公司新昌制药厂 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途
CA2802644C (en) 2010-06-25 2017-02-21 Eisai R & D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
KR101762999B1 (ko) 2011-04-18 2017-07-28 에자이 알앤드디 매니지먼트 가부시키가이샤 종양 치료제
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
RU2015115397A (ru) 2012-12-21 2017-01-25 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Аморфная форма производного хинолина и способ его получения
KR102204279B1 (ko) 2013-05-14 2021-01-15 에자이 알앤드디 매니지먼트 가부시키가이샤 자궁내막암 대상의 렌바티닙 화합물에 대한 반응성을 예측 및 평가하기 위한 생체표지
CN103396361B (zh) * 2013-07-24 2016-05-04 中国人民解放军第二军医大学 3,4-二氢异喹啉类抗肿瘤化合物及其制备方法与应用
PT3524595T (pt) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Derivado de quinolina altamente puro e método para produção do mesmo
EP3263106B1 (en) 2015-02-25 2023-10-25 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
CN104804008B (zh) * 2015-03-27 2016-03-23 亿腾药业（泰州）有限公司 一种工业化生产甲磺酸特拉替尼的方法
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
MX381976B (es) 2015-08-20 2025-03-13 Eisai R&D Man Co Ltd Agente terapéutico contra tumores.
BR112019014127A2 (pt) 2017-02-08 2020-02-11 Eisai R&D Management Co., Ltd. Composição farmacêutica para tratamento de tumores
CN107129502B (zh) * 2017-04-13 2022-08-05 泰州亿腾景昂药业股份有限公司 EOC315 Mod.I晶型化合物及其制备方法
SG11201910100PA (en) 2017-05-16 2019-11-28 Eisai R&D Man Co Ltd Treatment of hepatocellular carcinoma
CN112830932B (zh) * 2020-12-25 2022-04-08 泰州亿腾景昂药业股份有限公司 特拉替尼的游离碱晶型及其制备方法与用途
WO2023081923A1 (en) 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1453897A (fr) * 1965-06-16 1966-07-22 Dérivés du thiophène et de thiéno pyridazines
GB1094044A (en) * 1965-07-12 1967-12-06 Vantorex Ltd Phthalazine derivatives
FR1516777A (fr) * 1966-08-02 1968-02-05 Innothera Lab Sa Dérivés du thiazole ainsi que de la thiazolo [4,5-d] pyridazine et leur préparation
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
JPH03106875A (ja) * 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd １―（３―ピリジルメチル）フタラジン誘導体
CA2173493C (en) * 1994-08-09 2008-03-25 Nobuhisa Watanabe Fused pyridazine compounds
IL118631A (en) * 1995-06-27 2002-05-23 Tanabe Seiyaku Co History of pyridazinone and processes for their preparation
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CN1152031C (zh) * 1998-08-11 2004-06-02 诺瓦提斯公司 具有血管生成抑制活性的异喹啉衍生物
EP1165085B1 (en) * 1999-03-30 2006-06-14 Novartis AG Phthalazine derivatives for treating inflammatory diseases
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
ES2241781T3 (es) * 2000-02-09 2005-11-01 Novartis Ag Derivados de piridina inhibidores de la angiogenesis y/o del receptor tirosina quinasa de vegf.

Also Published As

Publication number Publication date
AR082231A2 (es) 2012-11-21
CN1420879A (zh) 2003-05-28
CA2385817A1 (en) 2001-04-05
KR20080086547A (ko) 2008-09-25
IL148880A0 (en) 2002-09-12
KR100895572B1 (ko) 2009-04-29
WO2001023375A3 (en) 2002-05-02
EP1228063B1 (en) 2009-02-11
CZ304767B6 (cs) 2014-10-08
EP1228063A2 (en) 2002-08-07
IL193367A (en) 2011-03-31
WO2001023375A2 (en) 2001-04-05
CN100422172C (zh) 2008-10-01
SK287417B6 (sk) 2010-09-07
SK5912002A3 (en) 2003-01-09
HU230223B1 (en) 2015-10-28
PE20010607A1 (es) 2001-07-12
CN100422173C (zh) 2008-10-01
CN100374435C (zh) 2008-03-12
BG106637A (bg) 2003-02-28
TW593315B (en) 2004-06-21
YU22902A (sh) 2004-12-31
CO5200835A1 (es) 2002-09-27
BG65860B1 (bg) 2010-03-31
HK1091819A1 (zh) 2007-01-26
HK1091818A1 (zh) 2007-01-26
MY143377A (en) 2011-05-13
AU1569601A (en) 2001-04-30
KR20080091505A (ko) 2008-10-13
BR0014382B1 (pt) 2014-04-01
ATE422494T1 (de) 2009-02-15
NO20021520D0 (no) 2002-03-26
ES2320525T3 (es) 2009-05-25
EE05258B1 (et) 2010-02-15
RS50369B (sr) 2009-11-10
MY135058A (en) 2008-01-31
IL193368A0 (en) 2009-02-11
KR100895571B1 (ko) 2009-04-29
ZA200202760B (en) 2003-10-29
MA25563A1 (fr) 2002-10-01
BR0014382A (pt) 2003-06-24
PL366342A1 (en) 2005-01-24
CZ20021444A3 (cs) 2002-08-14
IL193367A0 (en) 2009-02-11
NO20021520L (no) 2002-05-23
KR20020038775A (ko) 2002-05-23
CN1769282A (zh) 2006-05-10
CA2385817C (en) 2010-05-04
HRP20020308B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2013-01-31
NZ518589A (en) 2005-03-24
JP2003526632A (ja) 2003-09-09
IL193368A (en) 2011-05-31
GT200000158A (es) 2002-03-16
UA75053C2 (en) 2006-03-15
BRPI0014382B8 (pt) 2021-05-25
HUP0202704A3 (en) 2003-12-29
CN1769283A (zh) 2006-05-10
AR025752A1 (es) 2002-12-11
MY143580A (en) 2011-05-31
HRP20020308A2 (en) 2004-06-30
JP4919567B2 (ja) 2012-04-18
MXPA02003156A (es) 2002-09-30
HUP0202704A2 (hu) 2002-12-28
RU2260008C2 (ru) 2005-09-10
AU782820B2 (en) 2005-09-01
KR100890473B1 (ko) 2009-03-26
DOP2000000070A (es) 2002-02-28
PA8503201A1 (es) 2002-08-26
EE200200161A (et) 2003-08-15
AR082232A2 (es) 2012-11-21
PL205957B1 (pl) 2010-06-30

Similar Documents

Publication Publication Date Title
DE60041548D1 (de) Substituierte pyridine und pyridazine mit angiogenesis hemmender wirkung
ATE289592T1 (de) Substituierte pyridine mit herbizider wirkung
ATE330953T1 (de) Substituirte pyridine mit herbizider wirkung
ATE194832T1 (de) 2-aryl-substituierte pyridine
ATE249437T1 (de) Substituierte pyridine als selektive cyclooxygenase inhibitoren
DE69839398D1 (de) Pyridinderivate
DE69826841D1 (de) Phthalazines mit angiogenesis-hemmender wirkung
ATE309988T1 (de) Neue pyridin- und quinolin-derivate
NO994791D0 (no) Nikotinamid-derivater
DE60012213D1 (de) Fünfgliedrige n-heterocyclen mit hypoglykämischer und hypolipidemischer wirkung
BR9703890A (pt) Piridinas heterocíclicas fundidas
NO995340L (no) Ukonsolidert soneisolasjon og styring
ID17659A (id) Piridin campuran-bisiklik
ATE341546T1 (de) 4-trifluormethylpyrazolyl substituierte pyridine und pyrimidine
DE69521645D1 (de) Pyridinderivate
NO993823L (no) 2-Amino-6-(2-substituert-4-fenoksy)-substituerte pyridiner
DE10163359B4 (de) Pyridinderivat und dessen Komplex
ATE265448T1 (de) Substituierte pyridazinen und kondensierte pyridazinen mit angiogenesis-inhibierender wirkung
DE69837621D1 (de) Substituierte pyrimidine und pyridine als unkrautbekämpfungsmittel
ATE236124T1 (de) Herbizide 2,6-disubstituierte pyridine und 2,4- disubstituierte pyrimidine
DE59102729D1 (de) Substituierte Pyridine.
FI925825A7 (fi) Substituoidut pyridiini-N-oksidit, menetelmä niiden valmistamiseksi sekä niiden käyttö
FI941963L (fi) Pyridiinijohdannaiset, niiden valmistus ja käyttö
PT1149096E (pt) N-oxidos de piridina triciclicos agonistas de vasopressina
ATE271554T1 (de) Phenyl- und pyridyl-tetrahydro-pyridine mit tnf inhibitorischer wirkung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition